Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Mar 2

PMID 21359201

Citations 34

Authors

Arpita Kalla Vyas

Kai-Chien Yang

Dennis Woo

Anatoly Tzekov

Attila Kovacs

Patrick Y Jay

Paul W Hruz

Affiliations

Soon will be listed here.

Abstract

Background: There is growing awareness of secondary insulin resistance and alterations in myocardial glucose utilization in congestive heart failure. Whether therapies that directly target these changes would be beneficial is unclear. We previously demonstrated that acute blockade of the insulin responsive facilitative glucose transporter GLUT4 precipitates acute decompensated heart failure in mice with advanced dilated cardiomyopathy. Our current objective was to determine whether pharmacologic enhancement of insulin sensitivity and myocardial glucose uptake preserves cardiac function and survival in the setting of primary heart failure.

Methodology/principal Findings: The GLP-1 agonist exenatide was administered twice daily to a murine model of dilated cardiomyopathy (TG9) starting at 56 days of life. TG9 mice develop congestive heart failure and secondary insulin resistance in a highly predictable manner with death by 12 weeks of age. Glucose homeostasis was assessed by measuring glucose tolerance at 8 and 10 weeks and tissue 2-deoxyglucose uptake at 75 days. Exenatide treatment improved glucose tolerance, myocardial GLUT4 expression and 2-deoxyglucose uptake, cardiac contractility, and survival over control vehicle-treated TG9 mice. Phosphorylation of AMP kinase and AKT was also increased in exenatide-treated animals. Total myocardial GLUT1 levels were not different between groups. Exenatide also abrogated the detrimental effect of the GLUT4 antagonist ritonavir on survival in TG9 mice.

Conclusion/significance: In heart failure secondary insulin resistance is maladaptive and myocardial glucose uptake is suboptimal. An incretin-based therapy, which addresses these changes, appears beneficial.

Citing Articles

Type 2 diabetes mellitus' impact on heart failure patients' exercise tolerance: a focus on maximal fat oxidation during exercise.

Zhu H, Pan J, Wen J, Dang X, Chen X, Fan Y Front Cardiovasc Med. 2025; 12:1485755.

PMID: 39995969 PMC: 11847838. DOI: 10.3389/fcvm.2025.1485755.

Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway.

Ye H, He Y, Zheng C, Wang F, Yang M, Lin J Front Pharmacol. 2022; 13:816588.

PMID: 35308248 PMC: 8927800. DOI: 10.3389/fphar.2022.816588.

Review of Insulin Resistance in Dilated Cardiomyopathy and Implications for the Pediatric Patient Short Title: Insulin Resistance DCM and Pediatrics.

Mak D, Ryan K, Han J Front Pediatr. 2021; 9:756593.

PMID: 34778146 PMC: 8581153. DOI: 10.3389/fped.2021.756593.

Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl-induced Alzheimer-like pathology model.

Saleh R, F Eissa T, Abdallah D, Saad M, El-Abhar H Sci Rep. 2021; 11(1):12040.

PMID: 34103557 PMC: 8187628. DOI: 10.1038/s41598-021-90545-4.

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.

Helmstadter J, Keppeler K, Kuster L, Munzel T, Daiber A, Steven S Br J Pharmacol. 2021; 179(4):659-676.

PMID: 33764504 PMC: 8820186. DOI: 10.1111/bph.15462.

References

Sokos G, Nikolaidis L, Mankad S, Elahi D, Shannon R . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12(9):694-9. DOI: 10.1016/j.cardfail.2006.08.211. View

Sen P, Mukherjee S, Ray D, Raha S . Involvement of the Akt/PKB signaling pathway with disease processes. Mol Cell Biochem. 2003; 253(1-2):241-6. DOI: 10.1023/a:1026020101379. View

Liang G, Cai Q, Niu Y, Zheng H, Gao Z, Liu D . Cardiac glucose uptake and suppressed expression/translocation of myocardium glucose transport-4 in dogs undergoing ischemia-reperfusion. Exp Biol Med (Maywood). 2008; 233(9):1142-8. DOI: 10.3181/0801-RM-33. View

Hruz P, Yan Q, Struthers H, Jay P . HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J. 2008; 22(7):2161-7. DOI: 10.1096/fj.07-102269. View

Hom F, GOODNER C, Berrie M . A [3H]2-deoxyglucose method for comparing rates of glucose metabolism and insulin responses among rat tissues in vivo. Validation of the model and the absence of an insulin effect on brain. Diabetes. 1984; 33(2):141-52. DOI: 10.2337/diab.33.2.141. View

Shah A, Shannon R . Insulin resistance in dilated cardiomyopathy. Rev Cardiovasc Med. 2003; 4 Suppl 6:S50-7. View

Ashrafian H, Frenneaux M, Opie L . Metabolic mechanisms in heart failure. Circulation. 2007; 116(4):434-48. DOI: 10.1161/CIRCULATIONAHA.107.702795. View

Rodrigues B, Cam M, McNeill J . Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol. 1995; 27(1):169-79. DOI: 10.1016/s0022-2828(08)80016-8. View

Denissen J, Grabowski B, Johnson M, Buko A, Kempf D, Thomas S . Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997; 25(4):489-501. View

10.

Poornima I, Brown S, Bhashyam S, Parikh P, Bolukoglu H, Shannon R . Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2009; 1(3):153-60. PMC: 2733530. DOI: 10.1161/CIRCHEARTFAILURE.108.766402. View

11.

Kahn B, Alquier T, Carling D, Grahame Hardie D . AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1(1):15-25. DOI: 10.1016/j.cmet.2004.12.003. View

12.

Buerger A, Rozhitskaya O, Sherwood M, Dorfman A, Bisping E, Abel E . Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail. 2006; 12(5):392-8. DOI: 10.1016/j.cardfail.2006.03.002. View

13.

Bose A, Mocanu M, Carr R, Yellon D . Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther. 2005; 19(1):9-11. DOI: 10.1007/s10557-005-6892-4. View

14.

Schwenk R, Luiken J, Bonen A, Glatz J . Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008; 79(2):249-58. DOI: 10.1093/cvr/cvn116. View

15.

Asmar M, Holst J . Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes. 2009; 17(1):57-62. DOI: 10.1097/MED.0b013e3283339051. View

16.

Dyck J, Lopaschuk G . AMPK alterations in cardiac physiology and pathology: enemy or ally?. J Physiol. 2006; 574(Pt 1):95-112. PMC: 1817803. DOI: 10.1113/jphysiol.2006.109389. View

17.

Grieve D, Cassidy R, Green B . Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. Br J Pharmacol. 2009; 157(8):1340-51. PMC: 2765323. DOI: 10.1111/j.1476-5381.2009.00376.x. View

18.

Gros R, You X, Baggio L, Kabir M, Sadi A, Mungrue I . Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003; 144(6):2242-52. DOI: 10.1210/en.2003-0007. View

19.

Morissette M, Howes A, Zhang T, Brown J . Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2003; 35(10):1217-27. DOI: 10.1016/s0022-2828(03)00212-8. View

20.

Smith S, Young P, Cawthorne M . Quantification in vivo of the effects of insulin on glucose utilization in individual tissues of warm- and cold-acclimated rats. Biochem J. 1986; 237(3):789-95. PMC: 1147058. DOI: 10.1042/bj2370789. View